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IntroductIon
After the first reports of patients with AIDS 
in 1981, the discovery in 1983 of HIV as 
the etiological agent that causes AIDS and 
in 1984 of the CD4 protein as the main 
receptor for the virus our views on HIV 
pathology have been quite straightforward. 
Apparently HIV infects CD4+ human 
cells, which are mainly T helper cells, and 
in vitro studies show that these cells die 
in the course of a productive HIV infec-
tion. Thus, HIV is cytopathic for CD4+ T 
helper cells and this relates directly to very 
low CD4+ T helper cells in patients that 
present with AIDS symptoms and to the 
progressive loss of these cells in the course 
of HIV infection to AIDS. Indeed, in HIV 
infection the degree of depletion of CD4+ 
T cell numbers is since these days used as 
the main marker of disease progression 
(Fauci et al., 1996). This cytopathic model 
of AIDS pathogenesis has been boosted by 
two additional observations of very differ-
ent kinds. First, Ho et al. (1995) showed 
the true viral dynamics of HIV infection, 
making it clear that even in asymptomatic 
individuals daily production of HIV is very 
high, at least in the order of 10 (Grossman 
et al., 2002) viral particles per day, with a 
RT error rate that creates HIV tremendous 
variation and allows for rapid escape from 
drug and immune pressure. In addition, 
these authors reported high CD4+ T cell 
death rates and compensatory production 
of these cells which exhausts the immune 
system eventually depleting CD4+ T cells, 
the cause of AIDS. Second, in 1996 formal 
molecular proof was reported for two dis-
tinct co-receptors of HIV (Cocchi et al., 
1995; Feng et al., 1996) that explained the 
observation of HIV variants with different 
cytopathicity and with different cellular 
tropism (Tersmette et al., 1989; Koot et al., 
1993; Connor et al., 1997). Although in 
both immunology and virology there were 
problems regarding this cytopathic account 
of HIV/AIDS, not in the least because of the 
lack of a better comprehensive model, until 
very recently it has been the dominant view 
in textbooks and the literature.
chronIc InflammatIon drIves hIv 
assocIated dIsease
Our insights and ideas about AIDS patho-
genesis have gradually but drastically 
changed over the past decade and it is now 
widely held that the direct cytopathic effects 
of HIV do not, but the chronic inflammation 
that HIV induces does explain progression 
to AIDS (Hazenberg et al., 2000; McCune, 
2001; Grossman et al., 2002; Douek et al., 
2003). This is based on the fact that pro-
gression to disease is better predicted by the 
level of immune activation. Various mark-
ers of adaptive and innate immune activa-
tion are better and independent prognostic 
markers than CD4+ T cell numbers and 
viral load (Fahey et al., 1990; Giorgi et al., 
1999; Hazenberg et al., 2003; Deeks et al., 
2004). Furthermore, SIV monkey models 
strongly suggest that, even in the presence of 
high viral loads of cytopathic SIV, without 
chronic immune activation progression to 
disease is not observed, which corresponds 
to the rare non-progressing patients that 
have high viral loads (Silvestri et al., 2003). 
This has led to a view on HIV pathogenesis 
that is quite different from the classical cyto-
pathic model and which has implications 
for therapy and vaccine development. The 
recent finding that inflammation in non-
pathogenic SIV infection is actively down 
regulated by a gene expression program that 
is activated early after acute SIV infection 
prompts investigation into the mechanisms 
of that inhibitory gene expression and how 
it is started (Bosinger et al., 2009). In anal-
ogy, it will be key to understand why in 
humans in practically no infected individ-
ual an efficient and inhibitory gene expres-
sion profile is activated.
A first important insight from this devel-
opment is that in HIV infection, immune 
deficiency is the result of chronic activation 
of both the adaptive and innate immune 
system and is not an immediate effect of 
HIV infection. HIV induces activation of 
virtually all leukocyte populations (Deeks, 
2011) and in agreement with that in asymp-
tomatic but even in late stage HIV infec-
tion strong cellular and humoral immune 
responses are mounted from which the 
virus escapes, already in the first weeks 
after HIV infection, irrespective of the 
HLA background of the host, the virus is 
under severe pressure of cytotoxic T lym-
phocytes (CTL; Goonetilleke et al., 2009; 
Fischer et al., 2010). Leukocyte activation 
is reflected in activated cells, expression, 
and massive release of pro-inflammatory 
cytokines. Evidence for adaptive response 
has been complemented by our more recent 
insights that HIV single stranded (ss) RNA 
directly activates the innate immune sys-
tem via Toll like receptor (TLR) 7 and 8 in 
pDC and macrophages which causes the 
release of TNF alpha (Beignon et al., 2005; 
Meier et al., 2007). This has down-stream 
activating effects on NK, B cells, and CD4+ 
and CD8+ T cell and their turnover (Hardy 
et al., 2007). In addition, bacterial products, 
including LPS and peptidoglycans, translo-
cating from the gut are implied in driving 
immune activation even further. Bacterial 
translocation results from HIV associated 
depletion of CD4+ T cells from gut mucosa 
which affects gut integrity important to 
contain microbes in the GI tract (Brenchley 
et al., 2006). Further investigation to under-
stand the contribution of bacterial translo-
cation to immune activation is warranted.
non-aIds dIsease assocIated wIth 
hIv InfectIon
It is recognized that chronic inflamma-
tion underlies pathology in various clini-
cal conditions, obviously in autoimmune 
diseases, IBD, and Crohn’s disease, but also 
in atherosclerosis and cardiovascular dis-
ease (CVD), some neurological diseases 
and liver and kidney failure (Medzhitov, 
2010). Although initially cardiovascular, 
liver, and kidney disease was believed to be 
associated with side effects of some anti-
viral drugs, more recently HIV induced 
inflammation is thought to be implied also 
in these non-AIDS diseases (Bozzette et al., 
2003; El-Sadr et al., 2006). Although cART 
diminishes viral load and through that takes 
away most of the driver of inflammation, 
patients on long term cART have increased 
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Since the STEP trial was stopped in 2007 
because of a lack of effect on viral set point 
in vaccines after break through infection, 
vaccine development has been reevaluated. 
The concept of CTL based vaccines has been 
seriously questioned since it will not pro-
vide protection from infection and only 
temporarily slow down disease progres-
sion. Still, the idea of a CTL based vaccine 
has not been abandoned and encouraging 
and surprising results using a CMV based 
viral vector have just been reported in the 
SIV monkey model (Hansen et al., 2011). 
The field has at the same time seen a swing 
back to NeuAb and vaccine design based on 
the epitopes of broadly and potently NeuAb 
has been fueled by interesting novel NeuAb 
specificities that were recently reported (Wu 
et al., 2010; Zhou et al., 2010).
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therapy
cART is effectively used for more than 
15 years now and novel drugs targeting 
viral fusion are being developed and used. 
A serious problem is viral escape from anti-
virals and the transmission of drug-resistant 
variants, in developed and even more in 
developing countries were cART has been 
administered. Immune therapy by therapeu-
tic vaccination has not been successful and 
may be questioned as we now realize that 
immune activation is detrimental and spe-
cific immune response are strong (Autran 
et al., 2008). It could be that the quality of 
CTL and neutralizing antibodies (NeuAb) 
which prevail in chronic infection may be 
insufficient for control of HIV which may 
be eligible for restoration and enhancement 
(Betts et al., 2006). Similarly, immune ther-
apy such as with Il-7 has to be reconsidered 
because it activates the peripheral immune 
system (Sereti et al., 2009), although in com-
bination with cART this may be an option. 
When immune activation is a driver of dis-
ease before and after cART, inhibition of 
the various TLRs, cytokine responses such 
as TNF alpha and other inflammation path-
ways has to be considered at least to deal 
with non-AIDS end organ diseases. Novel 
genetic analyses using large data sets, more 
sequence information and novel bioinfor-
matics tools may help to define novel targets 
for therapeutic intervention in the immune 
system that are critical for disease progres-
sion or control of inflammation in HIV 
infected individuals. Finally it still remains 
the question whether the virus can be eradi-
cated from an infected host and what type of 
therapy would be required for that.
hIv specIfIc ImmunIty and hIv 
vaccInes
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protect from disease progression (Schellens 
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